Skip to content

Application Research of CEFFE Matrix in the Repair of Acne Scars and Traumatic Atrophic Scars

Application Research of CEFFE Matrix in the Repair of Acne Scars and Traumatic Atrophic Scars

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108687
Enrollment
Unknown
Registered
2025-09-03
Start date
2025-09-23
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic acne scars or atrophic scars caused by trauma/surgery

Interventions

Control Group:Punch Surgery + Autologous Nanofat Grafting
Study Group:Punch Surgery + CEFFE Matrix Grafting

Sponsors

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with severe facial atrophic acne scars or linear atrophic scars caused by trauma/surgery; 2.Acne or trauma has fully healed, with stable atrophic scars for more than 6 months; 3.Age: 18–60 years (inclusive), male or female; 4.Voluntary participation with signed informed consent and ability to comply with 6 months of treatment and follow-up; 5.No prior treatment for atrophic scars within the last 3 months; 6.Willing to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with allergy to lidocaine; 2.Women who are planning pregnancy, currently pregnant, or breastfeeding; 3.Patients with history of psychiatric disorders, severe psychological conditions, or major organ diseases that may interfere with long-term follow-up; 4.Patients with allergic predisposition or a family history of keloid/hypertrophic scar formation; 5.Patients with history of malignant tumors; 6.Patients with hematologic or immune system diseases that contraindicate surgery; 7.Patients with active facial infections, inflammation, herpes, psoriasis, or other autoimmune diseases, or those undergoing immunotherapy; 8.Patients who have participated in any other clinical trials within the past 3 months; 9.Other conditions deemed ineligible by the investigator.

Design outcomes

Primary

MeasureTime frame
Laboratory indicators;Overall Response Rate;Vital Signs;

Secondary

MeasureTime frame
VISIA Quantitative;Scales Score;3D Scanning Assessment and Quantitative ;Scar texture;

Countries

China

Contacts

Public ContactWei Liu

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

liuwei_md@126.com+86 21 53315601

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026